This activity is supported by an educational grant from AbbVie Inc.
Oncology NPs, PAs, and nurses
Upon completion of this activity, participants should be able to:
Describe current recommendations for risk stratification and molecular testing in AML
Summarize evidence supporting the appropriate use of novel therapies in AML
Apply recommended strategies to identify and manage toxicities of novel therapies in AML
All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Natasha L. Johnson, MS, ARNP, AOCNP: consultant/advisor/speaker: Abbvie, Taiho.
Melissa Dove, MSBS, PA-C, has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PACE staff have any relevant financial relationships to disclose.
Learners wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.50 hours.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.
Release date: September 28, 2022
Expiration date: September 27, 2023
Interactive, audio-enhanced slide lecture
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education (PACE), Practicing Clinicians Exchange, or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Natasha L. Johnson, MS, ARNP, AOCNP, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.50, which includes 1.50 hours of pharmacology credit
AAPA Credit Designation
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until September 27, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Melissa Dove, MSBS, PA-C, TriHealth Cancer Institute, Cincinnati, Ohio
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program has been made available online.